165 related articles for article (PubMed ID: 13680158)
1. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Riccardi A; Mazzarella G; Cefalo G; Garrè ML; Massimino M; Barone C; Sandri A; Ridola V; Ruggiero A; Mastrangelo S; Lazzareschi I; Caldarelli M; Maira G; Madon E; Riccardi R
Cancer Chemother Pharmacol; 2003 Dec; 52(6):459-64. PubMed ID: 13680160
[TBL] [Abstract][Full Text] [Related]
3. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
[TBL] [Abstract][Full Text] [Related]
4. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
Kirstein MN; Panetta JC; Gajjar A; Nair G; Iacono LC; Freeman BB; Stewart CF
Cancer Chemother Pharmacol; 2005 May; 55(5):433-8. PubMed ID: 15818507
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
Reid JM; Stevens DC; Rubin J; Ames MM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2393-8. PubMed ID: 9815639
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Aoki T; Nishikawa R; Mizutani T; Nojima K; Mishima K; Adachi J; Matsutani M
Int J Clin Oncol; 2007 Oct; 12(5):341-9. PubMed ID: 17929115
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
[TBL] [Abstract][Full Text] [Related]
8. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
Kim HK; Lin CC; Parker D; Veals J; Lim J; Likhari P; Statkevich P; Marco A; Nomeir AA
J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):225-33. PubMed ID: 9448080
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.
Ma J; Pulfer S; Li S; Chu J; Reed K; Gallo JM
Cancer Res; 2001 Jul; 61(14):5491-8. PubMed ID: 11454697
[TBL] [Abstract][Full Text] [Related]
10. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
Beale P; Judson I; Moore S; Statkevich P; Marco A; Cutler DL; Reidenberg P; Brada M
Cancer Chemother Pharmacol; 1999; 44(5):389-94. PubMed ID: 10501912
[TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Ostermann S; Csajka C; Buclin T; Leyvraz S; Lejeune F; Decosterd LA; Stupp R
Clin Cancer Res; 2004 Jun; 10(11):3728-36. PubMed ID: 15173079
[TBL] [Abstract][Full Text] [Related]
12. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
[TBL] [Abstract][Full Text] [Related]
15. Disposition and pharmacokinetics of temozolomide in rat.
Reyderman L; Statkevich P; Thonoor CM; Patrick J; Batra VK; Wirth M
Xenobiotica; 2004 May; 34(5):487-500. PubMed ID: 15370964
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
[TBL] [Abstract][Full Text] [Related]
18. Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Saleem A; Brown GD; Brady F; Aboagye EO; Osman S; Luthra SK; Ranicar AS; Brock CS; Stevens MF; Newlands E; Jones T; Price P
Cancer Res; 2003 May; 63(10):2409-15. PubMed ID: 12750260
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
[TBL] [Abstract][Full Text] [Related]
20. Analysis and stability study of temozolomide using capillary electrophoresis.
Andrasi M; Bustos R; Gaspar A; Gomez FA; Klekner A
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jul; 878(21):1801-8. PubMed ID: 20627825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
